Navigation Links
Neuralstem to Raise $7.0 Million in Registered Direct Offering
Date:9/13/2012

ROCKVILLE, Md., Sept. 13, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today announced the pricing of a registered direct offering of 7,000,000 shares of its common stock, offered at a price to the public of $1.00 per share.  The gross proceeds to Neuralstem from this offering are expected to be $7.0 million, before deducting placement agent fees and other estimated offering expenses payable by Neuralstem.  The offering is expected to close on or about September 19, 2012, subject to customary closing conditions.

(Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

Aegis Capital Corp. is acting as sole placement agent for this offering.

The offering is being made pursuant to a shelf registration statement that Neuralstem filed with the Securities and Exchange Commission ("SEC") and is effective.  A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and a final prospectus supplement and accompanying base prospectus will be filed with the SEC.  When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com. Electronic copies of the final prospectus supplement and accompanying base prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, anxiety, and post-traumatic stress disorder (PTSD).

Cautionary Statement Regarding Forward Looking Information                                                        

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuralstem Announces Proposed Public Offering
2. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
3. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
6. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
7. Neuralstem Updates ALS Stem Cell Trial Progress
8. BiO2 Medical Raises $12M in Series C Funding
9. ThinkCure! Weekend At Dodger Stadium Expected To Raise Hundreds Of Thousands Of Dollars For Cancer Research
10. Retia Medical Raises $7 Million to Develop Accurate, Less-Invasive Cardiovascular Monitor
11. Midwest Health Care Startups Raise $511 Million in First Half of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- France Glaucoma Surgery Devices Market Outlook to 2022 ... Devices Market Outlook to 2022", provides key market data ... provides value, in millions of US dollars, volume (in ... Canaloplasty Micro Catheters and Glaucoma Drainage Devices. The ... for each of these market segements, and global corporate-level ...
(Date:12/5/2016)... , Dec. 5, 2016   Mallinckrodt Pharmaceuticals ... specialty pharmaceutical company, today announced that it received a ... Equality Index (CEI), a national benchmarking survey and report ... bisexual and transgender (LGBT) workplace equality, administered by the ... of 517 major U.S. businesses which also earned top ...
(Date:12/5/2016)... 2016 INTRODUCTION Since ... emerged as a crucial class of pharmacological interventions ... antibiotics are also used for prophylactic purposes in ... (cancer patients undergoing chemotherapy). However, the inappropriate use ... has rapidly accelerated an evolutionary response of antibiotic ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those who believe ... hands. “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, ... that you could reach out for, and grab, on the old carousels. If ...
(Date:12/7/2016)... ... 07, 2016 , ... “Fred Rides a Train” allows readers to tag along ... “Fred Rides a Train” is the creation of published author, Janet Morrison, who has ... in Michigan. The "Fred, the Dog" series is her first attempt at writing for ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
(Date:12/6/2016)... ... ... Individuals who seek to reduce the effects of aging can take up ... to the sun, according to a November 30 article published on Medical ... while preventive measures to help keep ourselves looking our best always make sense, individuals ...
Breaking Medicine News(10 mins):